spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  dyspareunia 

 HSMN NewsFeed - 23 Oct 2018
Duchesnay Inc. Announces Submission of Supplemental New Drug Application (sNDA) for Osphena(R) (ospemifene) to U.S. FDA Seeking Approval for the Treatment of Vaginal Dryness, a Symptom of Vulvar and Vaginal Atrophy (VVA) Due to Menopause
Biopharmaceuticals FDA
 HSMN NewsFeed - 6 Sep 2017
AbbVie Submits New Drug Application to U.S. FDA for Investigational Oral Treatment Elagolix for the Management of Endometriosis with Associated Pain
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Apr 2017
AMAG Pharmaceuticals Announces Closing of Exclusive Licensing Agreement With Endoceutics for U.S. Rights to Intrarosa(TM) (Prasterone)
Biopharmaceuticals Licensing
 HSMN NewsFeed - 3 Mar 2016
Allergan Launches Bold Access To LILETTA(R) (levonorgestrel-releasing intrauterine system)
Biopharmaceuticals Drug Delivery Product Launch
 HSMN NewsFeed - 13 Apr 2015
Actavis and Medicines360 Announce U.S. Availability of LILETTA(TM) (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Three Years
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 10 Sep 2009
QuatRx Announces Positive Results of Second Pivotal Phase 3 Clinical Study for Ophena(TM) (Ospemifene Tablets) in Treatment of Postmenopausal Vaginal Atrophy
Biopharmaceuticals
 HSMN NewsFeed - 16 Jun 2008
Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy
Biopharmaceuticals
 HSMN NewsFeed - 21 May 2008
QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
Biopharmaceuticals
 HSMN NewsFeed - 3 Jan 2008
QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
Biopharmaceuticals
 HSMN NewsFeed - 8 Jan 2007
Urigen N.A., Inc. Appoints Dennis Giesing, PhD As Director of Product Development
Biopharmaceuticals Urology Personnel
 HSMN NewsFeed - 20 Dec 2006
Palatin Technologies and King Pharmaceuticals Complete Enrollment in Pre-Menopausal Cohort of a Phase 2 Clinical Trial Evaluating Bremelanotide in Pre- and Post-Menopausal Female Sexual Dysfunction Patients
Biopharmaceuticals
 HSMN NewsFeed - 29 Nov 2006
Urigen N.A., Inc. Appoints Terry M. Nida to Chief Operating Officer
Biopharmaceuticals Personnel
Return to NewsFeed  

 Additional items found! 20

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 20 additional stories matching:
dyspareunia
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!